Email this article Adiponectin and parameters of glucose and lipid metabolism at different clinical and morphological stages of non-alcoholic fatty liver disease in patients with abdominal obesity
- Authors: Komshilova KA1, Troshina EA1, Ershova EV1, Mazurina NV1, Platonova NM1
-
Affiliations:
- ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
- Issue: Vol 86, No 10 (2014)
- Pages: 27-32
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31563
- ID: 31563
Cite item
Full Text
Abstract
AIM. To compare clinical, laboratory, and morphological parameters in patients with abdominal obesity and non-alcoholic fatty liver disease (NAFLD) and to assess the relationship between the degree and stage of the disease and the cardiometabolic risk factors of type 2 diabetes mellitus and cardiovascular diseases. MATERIALS AND METHODS. Eighty patients aged 30 to 50 years with abdominal obesity were examined. NAFLD was diagnosed after liver puncture biopsy. The parameters of carbohydrate and lipid metabolism and the activity of hepatic transaminases and the protective adipocytokine adiponectin were investigated. RESULTS. NAFLD was verified in 77 examinees. Metabolic disturbances were found in the majority of the examinees with abdominal obesity and NAFLD; they were concurrent and increased in their rate and degree with the progression of NAFLD, obesity, and insulin resistance. The patients with NAFLD had a significantly decreased adiponectin level that got worse as NAFLD progressed. CONCLUSION. The investigation has revealed that NAFLD is associated with cardiometabolic disorders (dyslipidemia, carbohydrate metabolic disturbances, and insulin resistance) increasing in their rate and degree with the progression of NAFLD and the lower adiponectin level reducing as NAFLD worsens.
Full Text
##article.viewOnOriginalSite##About the authors
K A Komshilova
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
Email: komshilovaksenia@rambler.ru
E A Troshina
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
E V Ershova
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
N V Mazurina
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
N M Platonova
ФГБУ "Эндокринологический научный центр" Минздрава России, Москва
References
- Musso G, Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Rev 2010; 11 (6): 430-445.
- Stefan N., Kantartzis K., Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Rev 2008; 29 (7): 939-960.
- Никитин И.Г. Скрининговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания. Рос Мед Вести 2010; XV (1): 41-46.
- Browning J., Szczepaniak L., Dobbins R. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
- Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28 (4): 339-350.
- Fassio E., Alvarez E., Dominguez N. Natural history of non-alcoholic steatohepatitis: a longitudinal study of liver biopsies. Hepatology 2004; 40: 820-826.
- Bugianesi E., Gastaldelli A., Vanni E. et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetogia 2005; 48: 634-642.
- Cnop M., Havel P., Utzschneider K. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasms lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-469.
- Dowman J. K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103 (2): 71-83.
- Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации 2009. М: М-Вести.
- Mazhar S., Shiehmorteza M., Sirlin C. Noninvasive assessment of hepatic steatosis. Clin Gastroenterol Hepatol 2009; 7 (2): 135-140.
- Kleiner D.E., Brunt E.M., Van Natta M. et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41 (6): 1313-1321.
- Павлов Ч.С., Ивашкин В.Т. Биопсия печени: методология и практика сегодня. Рос журн гастроэнтерол, гепатол, колопроктол 2006; 4: 65-78.
- Tilg H., Diehl A., Li Z. et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-306.
- Marchesini G., Brizi M., Morselli-Labate A. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 (5): 450-455.
- Mofrad P., Contos M., Haque M. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
- Milner K., Van der Poorten D., Xu A. et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009; 49 (6): 1926-1934.
